Soho Global Health Tbk PT

Soho Global Health Tbk PT maintains a strong liquidity position, with a current ratio of 1.63, indicating the company can cover its short-term liabilities with its short-term assets. The company's free cash flow of 312.76 billion IDR and operating cash flow of 896.38 billion IDR support its liquidity profile, although its capital expenditures of -58.97 billion IDR suggest ongoing investment in operations. In terms of profitability, the company's return on equity of 23.24% and return on assets of 9.75% are strong, outperforming the typical benchmarks for the pharmaceutical industry. These metrics suggest that Soho Global Health Tbk PT is effectively utilizing its equity and assets to generate returns, which is a positive sign for investors. The company's revenue is primarily concentrated in Indonesia, with a significant portion of its operations and customer base located in the country. While the company has expanded into other Southeast Asian markets, its exposure to the Indonesian economy remains high, which could pose a concentration risk if the domestic market experiences economic downturns. Looking ahead, Soho Global Health Tbk PT is expected to maintain a stable growth trajectory, with its revenue and profitability likely to remain resilient due to the consistent demand for pharmaceutical products. The company's strong cash flow generation and low debt levels provide a solid foundation for future growth and reinvestment. The company's risk profile is characterized by a medium liquidity risk and a low dilution risk. The key risk flag is the negative net cash position after subtracting total debt, which could affect its ability to fund operations without external financing. However, the company's low debt-to-equity ratio of 0.0 suggests that it is not heavily leveraged, reducing the likelihood of financial distress. Recent events, including the company's financial performance and strategic initiatives, have been disclosed in its latest financial filings. These documents highlight the company's focus on expanding its product portfolio and strengthening its market position in Indonesia and beyond.